Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | SCN1A | P35498 | 1/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.58 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5925544 | 0.89 | CYP1A2 (0.72) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL8717028 | 0.87 | CYP1A2 (0.47) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL755147 | 0.87 | ALDH1A1 (0.63) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL6588826 | 0.87 | LMNA (0.53) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL2337419 | 0.87 | TDP1 (0.62) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL16005488 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL31107344 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL24074069 | 0.83 | TSHR (0.61) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL578910 | 0.83 | ALDH1A1 (0.67) | CYP1A2CYP2D6SCN1ASCN2ASCN3A | |
| SCHEMBL6154000 | 0.83 | MKNK1 (0.55) | CYP1A2CYP2D6SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| US-4221815-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | CYP1A2 892/4885CYP2D6 1183/4885SCN1A 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.